Federal Register: December 20, 2004 (Volume 69, Number 243)
DOCID: FR Doc 04-27736
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
Docket ID: [Docket No. 2004D-0524]
ACTION: Reports and guidance documents; availability, etc.:
DOCUMENT ACTION: Notice.
Draft Guidance for Industry on ANDAs: Pharmaceutical Solid Polymorphism; Chemistry, Manufacturing, and Controls Information; Availability
DATES: Submit written or electronic comments on the draft guidance by March 21, 2005. General comments on
agency guidance documents are welcome at any time.
The Food and Drug Administration (FDA) is announcing the availability of a draft guidance for industry entitled ``ANDAs: Pharmaceutical Solid Polymorphism; Chemistry, Manufacturing, and Controls Information.'' The draft guidance is intended to assist applicants with the submission of abbreviated new drug applications (ANDAs) when a drug substance exists in polymorphic forms.
ANDAs; pharmaceutical solid polymorphism; chemistry, manufacturing, and controls information,
FDA is announcing the availability of a draft guidance for industry entitled ``ANDAs: Pharmaceutical Solid Polymorphism; Chemistry, Manufacturing, and Controls Information.'' This draft guidance provides: (1) A framework for making regulatory decisions on drug substance sameness in terms of polymorphic form, and (2) decision trees which provide a recommended course to monitor and control polymorphs in the drug substance and/or drug product when the drug substance exists in relevant polymorphic forms.
This draft guidance is being issued consistent with FDA's good guidance practices regulation (21 CFR 10.115). The draft guidance, when finalized, will represent the agency's current thinking on pharmaceutical solid polymorphism. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. An alternative approach may be used if such approach satisfies the requirements of the applicable statutes and regulations. II. Comments
Interested persons may submit to the Division of Dockets Management (see ADDRESSES) written or electronic comments on the draft guidance. Two copies of any comments are to be submitted, except that individuals may submit one copy. Comments are to be identified with the docket number found in brackets in the heading of this document. The draft guidance and received comments are available for public examination in the Division of Dockets Management between 9 a.m. and 4 p.m., Monday through Friday.
III. Electronic Access
Persons with access to the Internet may obtain the document at http://www.fda.gov/ohrms/dockets/default.htm.
Dated: December 11, 2004.
Assistant Commissioner for Policy.
[FR Doc. 0427736 Filed 121704; 8:45 am]
BILLING CODE 416001S
FOR FURTHER INFORMATION CONTACT
Andre Raw, Center for Drug Evaluation and Research (HFD620), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 3018275758.